Clinical trials: Heparin-induced Thrombocytopenia
Heparin-induced Thrombocytopenia
A Phase I Study of the Co-administration of VLX-1005 and Argatroban in Healthy Human Subjects
The study is designed to characterize the safety and tolerability of VLX-1005 and argatroban administered intravenously, either alone or in combination; and the pharmacokinetics and pharmacodynamics and potential interaction of…
- Trial name
- NCT05325346
- Testing
- VLX-1005, Argatroban
- Where
- United States
- Volunteers
- 12 people, healthy volunteers welcome
- Sponsor
- Veralox Therapeutics
Heparin-induced Thrombocytopenia (HIT)
Optimizing the Diagnosis of Heparin Induced Thrombocytopenia
Multicentre (Ottawa and Halifax) prospective cohort study using a diagnostic approach in patients clinically suspected to have HIT that combines pretest probability assessment with quantitative interpretation of anti-PF4 assay.
- Trial name
- HIT (NCT03148912)
- Testing
- Diagnostic algorithm
- Where
- Canada
- Volunteers
- 107 people
- Sponsor
- Ottawa Hospital Research Institute
Heparin Induced Thrombocytopenia
Heparin-Induced Thrombocytopenia - Retrospective Analysis of Data on Incidence and Outcomes Study
HIT-RADIO is a study of patients who had a positive heparin PF-4 antibody test between 1/21/2008 and 9/25/2008 at selected hospitals.
- Trial name
- HIT-RADIO (NCT01178333)
- Where
- 21 sites in United States
- Volunteers
- 668 people
- Sponsor
- Carelon Research
Heparin-Induced Thrombocytopenia
Heparin Antibodies in Intensive Care Unit Patients (HAICU)
Intensive care unit patients have multiple risk factors for venous thromboembolism. Venous thromboembolism leads to significant morbidity and can be fatal.
- Trial name
- NCT00283322
- Testing
- blood samples (2)
- Where
- 2 sites in United States
- Volunteers
- 185 people
- Sponsor
- The University of Texas Health Science Center, Houston
Platelet Disorder, Heparin-induced Thrombocytopenia
PLATELET Function Assay With Flow Imaging on ImageSTREAM Cytometer
Platelets are essential blood elements to maintain hemostasis. Quantitative or qualitative defects can be responsible of hemorrhagic (platelet disorders) or thrombotic (heparin induced thrombocytopenia [HIT]) troubles.
- Conditions
- Platelet Disorder, Heparin-induced Thrombocytopenia, Platelet Activation, Platelet Aggregation
- Trial name
- PLATELETSTREAM (NCT04842760)
- Where
- France
- Volunteers
- 31 people
- Sponsor
- Centre Hospitalier Universitaire, Amiens
Heparin-Induced Thrombocytopenia, Thrombosis
Thrombotic Biomarkers to Predict Thrombosis in Heparin-induced Thrombocytopenia
Heparin induced thrombocytopenia (HIT) is a kind of catastrophic thrombotic complications after the application of heparin. If HIT without treatment, death rate is as high as 30% to 50%.
- Conditions
- Heparin-Induced Thrombocytopenia, Thrombosis, Biomarkers
- Trial name
- NCT03269019
- Testing
- HIT with thrombosis
- Volunteers
- 200 people
- Sponsor
- Wuhan Asia Heart Hospital
Heparin Induced Thrombocytopenia (HIT)
Heparin Induced Thrombocytopenia: Pharmacoeconomics
Patients at BWH receiving unfractionated heparin or enoxaparin who subsequently develop heparin induced thrombocytopenia will be identified via a computer generated report designed for the purposes of this study.
- Trial name
- NCT00456001
- Where
- United States
- Volunteers
- 200 people
- Sponsor
- Brigham and Women's Hospital
Heparin-induced Thrombocytopenia
Cangrelor As Treatment for Cardiac Surgery Associated With Heparin Induced Thrombocytopenia
Heparin-induced thrombocytopenia (HIT) is a rare but serious immune complication of heparin exposure that paradoxically increases the risk of thrombosis.
- Trial name
- CATCH-IT (NCT07817680)
- Where
- France
- Volunteers
- 132 people
- Sponsor
- Société Française d'Anesthésie et de Réanimation
Thrombocytopenia, Immune, Heparin Induced Thrombocytopenia
A Phase 2 Study of VLX-1005 Versus Placebo in Suspected Heparin Induced Thrombocytopenia
The purpose of this study is to evaluate the efficacy and safety of VLX-1005, a 12-lipoxygenase (12-LOX) enzyme inhibitor in treating heparin induced thrombocytopenia (HIT).
- Trial name
- NCT05785819
- Testing
- VLX-1005
- Where
- 14 sites in United States
- Volunteers
- 24 people
- Sponsor
- Veralox Therapeutics
Thrombocytopenia, Thrombosis
Evaluation of Argatroban Injection in Pediatric Patients Requiring Anticoagulant Alternatives to Heparin
The purpose of this study is to evaluate the safe and effective dose of Argatroban for prophylaxis and/or treatment of thrombosis in pediatric patients with current or previous diagnosis of heparin-induced thrombocytopenia (HIT)…
- Trial name
- NCT00039858
- Testing
- Argatroban
- Where
- 13 sites in United States
- Volunteers
- 24 people
- Sponsor
- Encysive Pharmaceuticals
Heparin-induced Thrombocytopenia, Heparin-induced Thrombocytopenia and Thrombosis
Efficacy and Safety of Apixaban in the Treatment of Heparin Induced Thrombocytopenia (HIT)
This research study is studying a drug as a possible treatment for heparin induced thrombocytopenia (HIT) or Heparin-induced Thrombocytopenia and Thrombosis (HITT). The drug involved in this study is apixaban.
- Trial name
- NCT03594045
- Testing
- Apixaban
- Where
- 3 sites in United States
- Volunteers
- 5 people
- Sponsor
- Massachusetts General Hospital
Heparin-Induced Thrombocytopenia
The HIT-TRAP Trial
Randomised, double blind trial in non-intensive care trauma patients comparing unfractionated heparin (UFH) or low-molecular-weight heparin (LMWH) in heparin-induced thrombocytopenia (HIT).
- Trial name
- NCT00196417
- Testing
- Standard heparin (UFH) versus certoparin (LMWH)
- Where
- Germany
- Volunteers
- 600 people
- Sponsor
- University Medicine Greifswald
Cardiovascular Disease, Coronary Artery Bypass Surgery
Angiomax in Patients With HIT/HITTS Type II Undergoing CPB
The purpose of this study is to demonstrate that in patients with heparin-induced thrombocytopenia (HIT)/heparin-induced thrombocytopenia and thrombosis syndrome (HITTS) Type II undergoing cardiac surgery on cardiopulmonary…
- Trial name
- HIT/TS (NCT00079508)
- Testing
- Angiomax (bivalirudin)
- Where
- United States
- Volunteers
- 125 people
- Sponsor
- The Medicines Company
Acute HIT II (Heparin-induced Thrombocytopenia Type II)
Retrospective Registry of Patients With Acute Heparin-induced Thrombocytopenia Type II
The purpose of this retrospective registry is to collect data about patients with acute HIT II (Heparin-induced Thrombocytopenia type II) which were treated with Lepirudin, Danaparoid, Argatroban or Fondaparinux.
- Trial name
- NCT01304238
- Testing
- lepirudin, danaparoid, argatroban
- Volunteers
- 195 people
- Sponsor
- GlaxoSmithKline
Suspected Heparin-Induced Thrombocytopenia
A Comparative Sudy Comparing Argatroban® IV vs Desirudin SC for Suspected HIT With or Without Thrombosis Syndrome
Compare Clinical Success and Costs in two Arms
- Trial name
- HIT (NCT00787332)
- Testing
- Desirudin or Argatroban®
- Where
- 24 sites in United States
- Volunteers
- 16 people
- Sponsor
- Canyon Pharmaceuticals, Inc.
Thrombocytopenia
Evaluating the Presence of Blood Clots in People With Heparin-Induced Thrombocytopenia (HIT) (The HOT Study)
Heparin-induced thrombocytopenia (HIT), a condition characterized by low platelet levels and possible blood clots, occurs in a small number of people after treatment with the drug heparin.
- Trial name
- HOT (NCT00594685)
- Where
- 21 sites in United States
- Volunteers
- 10 people
- Sponsor
- Carelon Research
Aneurysmal Subarachnoid Hemorrhage, Neurobehavioral Manifestations
Aneurysmal Subarachnoid Hemorrhage Trial RandOmizing Heparin
A Blind-adjudication Multi-center Phase II Randomized Clinical Trial of Continuous Low-dose Intravenous Heparin Therapy in Coiled Low-grade Aneurysmal Subarachnoid Hemorrhage Patients with Significant Hemorrhage Burden.
- Conditions
- Aneurysmal Subarachnoid Hemorrhage, Neurobehavioral Manifestations, Vasospasm, Intracranial, Intracranial Aneurysm
- Trial name
- ASTROH (NCT02501434)
- Testing
- Continuous Low-Dose IV Unfractionated Heparin Infusion
- Where
- 9 sites in United States
- Volunteers
- 88 people
- Sponsor
- Robert F. James
Heparin-induced Thrombocytopenia
Argatroban Monitoring in Critically Ill Patients: Evaluation of a Novel Ecarin-based Bedside Test
Argatroban is a parenteral direct Thrombininhibitor used for anticoagulation in patients suffering from heparin induced thrombocytopenia (HIT).
- Trial name
- NCT04751357
- Testing
- ECA-Test (Clot-Pro)
- Where
- Austria
- Volunteers
- 21 people
- Sponsor
- Medical University of Vienna
Thrombocytopenia, Thrombosis
Angiomax in Patients With HIT/HITTS Type II Undergoing Off-Pump Coronary Artery Bypass Grafting (CABG) (CHOOSE)
The purpose of this study is to examine the safety and efficacy of Angiomax as an anticoagulation in patients with heparin-induced thrombocytopenia (HIT)/heparin-induced thrombocytopenia with thrombosis syndrome (HITTS)…
- Conditions
- Thrombocytopenia, Thrombosis, Cardiac Disease, Coronary Artery Bypass Surgery
- Trial name
- NCT00073580
- Testing
- Angiomax (bivalirudin) anticoagulant
- Where
- United States
- Volunteers
- 88 people
- Sponsor
- The Medicines Company
Dialysis; Complications, Heparin-induced Thrombocytopenia
Multicenter Study on Dialysis Modalities for End-stage Chronic Renal Failure Patients With Heparin-induced Thrombocytopenia
This research is based on the hypothesis that the Hydrolink®-NV dialysis membrane could allow the realization of quality dialysis with a significant reduction in the doses of Orgaran®, or even a total cessation of the…
- Conditions
- Dialysis; Complications, Heparin-induced Thrombocytopenia, Chronic Renal Failure
- Trial name
- MODIATIH (NCT05586854)
- Testing
- Hydrolink NV membrane
- Where
- France
- Volunteers
- 20 people
- Sponsor
- GCS Ramsay Santé pour l'Enseignement et la Recherche